Targeting the mGluR5-GLT-1 axis may, therefore, provide a promising therapeutic strategy to restore glutamatergic homeostasis and mitigate PTSD-related neurobiological dysfunction, as this imbalance is thought to underline key features of PTSD, including cognitive deficits and impaired fear extinction. Here, GRM5 is linked to Cognitive impairment.